Palbociclib Ups PFS in HER2−/ER+ Breast Cancer

Abstract The experimental CDK-inhibitor palbociclib, when combined with the aromatase inhibitor letrozole, significantly extended progression-free survival in women with HER2-/ER+ breast cancer compared with letrozole alone, according to the final results from a phase II clinical trial of the drug.